Chemed Lags Peers as Short Interest Holds Near Recent Highs

Chemed Corporation has drifted lower against its peer group this week, even as the pre-earnings short build that drove positioning to a one-month peak begins to ease at the margins.

Among the closest correlated healthcare names, Ensign Group fell 3.7% over the past week and UHS dropped 4.5%, making Chemed's 1.4% decline look relatively contained in absolute terms. But the median weekly move across the peer set is roughly flat to modestly positive, and Addus HomeCare gained 2.7%. Chemed is trailing where most of its comparison group has at least held ground, which puts more focus on the company's own position than on sector rotation.

Short interest pulled back marginally on October 27, down less than 1% on the day to around 690,000 shares. That still leaves it 19% higher than it was a week ago and nearly 23% above its level a month earlier, with the current reading at 4.9% of the free float. The borrow market is relaxed: cost to borrow has eased to 0.41% after touching 0.50% earlier in the week, and availability remains very deep, with shares available to lend running at more than 50 times current short interest. There is no squeeze pressure here. The short score has also drifted up over the past two weeks, from around 38.9 on October 19 to 42.5 now, consistent with the rebuilding short position rather than any fundamental pressure from the lending side.

Options positioning adds little to the story either way. The put/call ratio of 1.05 is essentially identical to its 20-day average of 1.05, and the z-score of 0.32 is unremarkable. Neither side is paying up for protection or upside in any unusual way. That is notable given earnings were due today: the previous quarterly result in July produced a 3.3% gain on the day and 5.6% over the following five sessions, but the options market has not moved to price in a directional bet.

The analyst picture is broadly constructive but not unanimously so. UBS initiated coverage in late September with a Buy rating and a $650 target, placing it at the bullish end of a range that spans down to RBC Capital's Sector Perform at $548. BofA holds a Neutral at $510, which is below where the stock currently trades. The mean target of $593 implies roughly 16% upside from the $509 close. The bull case centres on long-term demand growth in the VITAS hospice segment and an expected rebound in 2026. Bears point to a 520 basis point compression in Roto-Rooter's adjusted EBITDA margin and softening lead generation as signs that profitability is under pressure in the plumbing segment. Chemed's PE multiple of 18.7 has drifted down about 0.3 points over the past month, a modest de-rating but not dramatic. The dividend score ranks in the 98th percentile, reflecting the company's consistent payout history.

On the insider side, CEO Kevin McNamara sold 2,000 shares in late September at around $513, his second open-market sale in as many months. Neither transaction was under a 10b5-1 plan. Net insider activity over the past 90 days amounts to a disposal of roughly 9,200 shares worth about $4.8 million. Most of the gross buying activity in the period was tied to option exercises and associated tax-withholding sales rather than open-market conviction purchases, so the net figure overstates the directional signal somewhat. Still, the pattern of CEO discretionary selling into the mid-$500s is worth noting against a stock now trading in the low $500s.

The next number that changes the picture is the Q3 earnings print, due today. The short position is elevated relative to recent history but the borrow market remains wide open, and the analyst community has plenty of room to move targets meaningfully in either direction given the spread between the $510 floor and the $650 ceiling.